Nycomed Amersham Imaging and Novation Announce Contract Extension

Extension Allows VHA and UHC Members to Use Nycomed Amersham Products as

Part of Novation's OPPORTUNITY(R) Spectrum Portfolios



Apr 02, 2001, 01:00 ET from Nycomed Amersham Imaging

    LONDON, and IRVING, Texas, April 2 /PRNewswire/ -- Nycomed Amersham
 Imaging (NYSE:   NYE; LSE: NAM) the leader in medical diagnostics and a major
 provider of radiotherapy products, and Novation, the supply company of VHA
 Inc. and University HealthSystem Consortium, announced today that they have
 agreed to a contract extension to provide VHA and UHC health care
 organizations with Nycomed Amersham Imaging's full line of x-ray and MRI
 contrast media products until March 31, 2005.
     This extension enables health care organizations electing to participate
 in Novation's OPPORTUNITY Spectrum portfolios to continue to use Nycomed
 Amersham's products for the full term of the portfolios. OPPORTUNITY is
 Novation's committed program that rewards VHA and UHC members based on their
 ability to commit to certain agreements the company offers.
     This exclusive agreement, which began on January 1, 1999, offers
 significant business potential to Nycomed Amersham Imaging while providing
 superior benefit to Nycomed Amersham Imaging and Novation customers.
     Under the terms of the agreement, Nycomed Amersham Imaging will provide
 VHA and UHC members with Omnipaque(R) (iohexol) and Omniscan(R) (gadodiamide)
 under the Novation private label, NOVAPLUS(TM). Also included in the agreement
 are: Visipaque(R) (iodixanol), the first nonionic isosmolar contrast agent,
 Teslascan(R) (mangafodipir trisodium), a contrast agent specifically for the
 liver, and Hypaque(R) (diatrizoate). Under terms of the original agreement,
 Nycomed Amersham Imaging will also supply products to health care
 organizations that purchase supplies through HealthCare Purchasing Partners
 International LLC, Novation's companion company that is owned by VHA and UHC.
     "Nycomed Amersham has been business partners with VHA and University
 HealthSystem Consortium for more than a decade, and we are delighted that will
 be able to continue to serve VHA, UHC and HPPI members with our x-ray and MRI
 products and participate in the OPPORTUNITY Spectrum portfolios," said Daniel
 L. Peters, President of Nycomed Amersham Imaging's Medical Diagnostics
 Worldwide.
     Contrast agents marketed by Nycomed Amersham Imaging are used in x-ray
 imaging, computed tomography (CT) scanning, magnetic resonance imaging (MRI),
 and nuclear imaging.  Contrast and nuclear medicine imaging agents are, in
 general, ingested or injected into the bloodstream to enhance images of the
 structure or functioning of body organs obtained during diagnostic imaging
 procedures.  These enhanced diagnostic images enable physicians to more
 accurately detect, diagnose, and treat diseases and functional abnormalities.
 In addition, Nycomed Amersham Imaging has nuclear oncology products, some of
 which are used to treat localized tumors such as prostate cancer, and another,
 which is used to treat pain from cancer that has spread to the bone.
 
     Nycomed Amersham Imaging is committed to finding innovative diagnostic and
 therapeutic solutions in cardiology, pulmonology, neurology and oncology. The
 Company is part of Nycomed Amersham plc, the world leader in in-vivo
 diagnostic imaging and life sciences. Based in the United Kingdom, the company
 has annual sales of 1.4 billion pounds sterling (approximately U.S. $2.1
 billion) and around 8,900 employees worldwide.
     For additional information, visit the Nycomed Amersham plc corporate Web
 site at http://www.nycomed-amersham.com.
 
     Novation was established January 1, 1998, through the combination of the
 supply programs of VHA Inc. and the University HealthSystem Consortium, two
 national health care alliances.  The largest supply chain management company
 in health care, Novation manages more than $17 billion in annual purchases for
 more than 7,200 VHA, UHC and HPPI members and affiliates. For more information
 on Novation, go to http://www.novationco.com
 
 

SOURCE Nycomed Amersham Imaging
    LONDON, and IRVING, Texas, April 2 /PRNewswire/ -- Nycomed Amersham
 Imaging (NYSE:   NYE; LSE: NAM) the leader in medical diagnostics and a major
 provider of radiotherapy products, and Novation, the supply company of VHA
 Inc. and University HealthSystem Consortium, announced today that they have
 agreed to a contract extension to provide VHA and UHC health care
 organizations with Nycomed Amersham Imaging's full line of x-ray and MRI
 contrast media products until March 31, 2005.
     This extension enables health care organizations electing to participate
 in Novation's OPPORTUNITY Spectrum portfolios to continue to use Nycomed
 Amersham's products for the full term of the portfolios. OPPORTUNITY is
 Novation's committed program that rewards VHA and UHC members based on their
 ability to commit to certain agreements the company offers.
     This exclusive agreement, which began on January 1, 1999, offers
 significant business potential to Nycomed Amersham Imaging while providing
 superior benefit to Nycomed Amersham Imaging and Novation customers.
     Under the terms of the agreement, Nycomed Amersham Imaging will provide
 VHA and UHC members with Omnipaque(R) (iohexol) and Omniscan(R) (gadodiamide)
 under the Novation private label, NOVAPLUS(TM). Also included in the agreement
 are: Visipaque(R) (iodixanol), the first nonionic isosmolar contrast agent,
 Teslascan(R) (mangafodipir trisodium), a contrast agent specifically for the
 liver, and Hypaque(R) (diatrizoate). Under terms of the original agreement,
 Nycomed Amersham Imaging will also supply products to health care
 organizations that purchase supplies through HealthCare Purchasing Partners
 International LLC, Novation's companion company that is owned by VHA and UHC.
     "Nycomed Amersham has been business partners with VHA and University
 HealthSystem Consortium for more than a decade, and we are delighted that will
 be able to continue to serve VHA, UHC and HPPI members with our x-ray and MRI
 products and participate in the OPPORTUNITY Spectrum portfolios," said Daniel
 L. Peters, President of Nycomed Amersham Imaging's Medical Diagnostics
 Worldwide.
     Contrast agents marketed by Nycomed Amersham Imaging are used in x-ray
 imaging, computed tomography (CT) scanning, magnetic resonance imaging (MRI),
 and nuclear imaging.  Contrast and nuclear medicine imaging agents are, in
 general, ingested or injected into the bloodstream to enhance images of the
 structure or functioning of body organs obtained during diagnostic imaging
 procedures.  These enhanced diagnostic images enable physicians to more
 accurately detect, diagnose, and treat diseases and functional abnormalities.
 In addition, Nycomed Amersham Imaging has nuclear oncology products, some of
 which are used to treat localized tumors such as prostate cancer, and another,
 which is used to treat pain from cancer that has spread to the bone.
 
     Nycomed Amersham Imaging is committed to finding innovative diagnostic and
 therapeutic solutions in cardiology, pulmonology, neurology and oncology. The
 Company is part of Nycomed Amersham plc, the world leader in in-vivo
 diagnostic imaging and life sciences. Based in the United Kingdom, the company
 has annual sales of 1.4 billion pounds sterling (approximately U.S. $2.1
 billion) and around 8,900 employees worldwide.
     For additional information, visit the Nycomed Amersham plc corporate Web
 site at http://www.nycomed-amersham.com.
 
     Novation was established January 1, 1998, through the combination of the
 supply programs of VHA Inc. and the University HealthSystem Consortium, two
 national health care alliances.  The largest supply chain management company
 in health care, Novation manages more than $17 billion in annual purchases for
 more than 7,200 VHA, UHC and HPPI members and affiliates. For more information
 on Novation, go to http://www.novationco.com
 
 SOURCE  Nycomed Amersham Imaging